nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprazolam—CYP3A4—Thiotepa—urinary bladder cancer	0.0401	0.314	CbGbCtD
Alprazolam—CYP3A5—Etoposide—urinary bladder cancer	0.0278	0.218	CbGbCtD
Alprazolam—CYP2C9—Fluorouracil—urinary bladder cancer	0.0224	0.175	CbGbCtD
Alprazolam—CYP2C9—Cisplatin—urinary bladder cancer	0.019	0.149	CbGbCtD
Alprazolam—CYP3A4—Etoposide—urinary bladder cancer	0.0109	0.0851	CbGbCtD
Alprazolam—Midazolam—CYP4B1—urinary bladder cancer	0.00908	0.389	CrCbGaD
Alprazolam—CYP3A4—Doxorubicin—urinary bladder cancer	0.00741	0.0581	CbGbCtD
Alprazolam—Clonazepam—NAT2—urinary bladder cancer	0.00563	0.241	CrCbGaD
Alprazolam—Flunitrazepam—UGT2B7—urinary bladder cancer	0.00486	0.208	CrCbGaD
Alprazolam—Oxazepam—UGT2B7—urinary bladder cancer	0.00378	0.162	CrCbGaD
Alprazolam—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000738	0.000951	CcSEcCtD
Alprazolam—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000738	0.000951	CcSEcCtD
Alprazolam—Hepatitis—Methotrexate—urinary bladder cancer	0.000734	0.000946	CcSEcCtD
Alprazolam—Sweating—Epirubicin—urinary bladder cancer	0.000733	0.000945	CcSEcCtD
Alprazolam—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000733	0.000945	CcSEcCtD
Alprazolam—Asthenia—Gemcitabine—urinary bladder cancer	0.000731	0.000942	CcSEcCtD
Alprazolam—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000725	0.000934	CcSEcCtD
Alprazolam—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000725	0.000934	CcSEcCtD
Alprazolam—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000724	0.000932	CcSEcCtD
Alprazolam—Weight increased—Doxorubicin—urinary bladder cancer	0.000723	0.000931	CcSEcCtD
Alprazolam—Epistaxis—Epirubicin—urinary bladder cancer	0.000722	0.00093	CcSEcCtD
Alprazolam—Pruritus—Gemcitabine—urinary bladder cancer	0.000721	0.000929	CcSEcCtD
Alprazolam—Nausea—Thiotepa—urinary bladder cancer	0.00072	0.000927	CcSEcCtD
Alprazolam—Urethral disorder—Methotrexate—urinary bladder cancer	0.000719	0.000927	CcSEcCtD
Alprazolam—Weight decreased—Doxorubicin—urinary bladder cancer	0.000718	0.000925	CcSEcCtD
Alprazolam—Feeling abnormal—Etoposide—urinary bladder cancer	0.000717	0.000924	CcSEcCtD
Alprazolam—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000712	0.000917	CcSEcCtD
Alprazolam—Pruritus—Fluorouracil—urinary bladder cancer	0.000709	0.000914	CcSEcCtD
Alprazolam—Infestation—Doxorubicin—urinary bladder cancer	0.000708	0.000912	CcSEcCtD
Alprazolam—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000708	0.000912	CcSEcCtD
Alprazolam—Drowsiness—Doxorubicin—urinary bladder cancer	0.000708	0.000912	CcSEcCtD
Alprazolam—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000702	0.000904	CcSEcCtD
Alprazolam—Hypersensitivity—Cisplatin—urinary bladder cancer	0.0007	0.000902	CcSEcCtD
Alprazolam—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000697	0.000899	CcSEcCtD
Alprazolam—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000694	0.000894	CcSEcCtD
Alprazolam—Urticaria—Etoposide—urinary bladder cancer	0.000692	0.000891	CcSEcCtD
Alprazolam—Jaundice—Doxorubicin—urinary bladder cancer	0.00069	0.000889	CcSEcCtD
Alprazolam—Abdominal pain—Etoposide—urinary bladder cancer	0.000688	0.000887	CcSEcCtD
Alprazolam—Body temperature increased—Etoposide—urinary bladder cancer	0.000688	0.000887	CcSEcCtD
Alprazolam—Hepatitis—Epirubicin—urinary bladder cancer	0.000687	0.000885	CcSEcCtD
Alprazolam—Eye disorder—Methotrexate—urinary bladder cancer	0.000686	0.000884	CcSEcCtD
Alprazolam—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000686	0.000884	CcSEcCtD
Alprazolam—Tinnitus—Methotrexate—urinary bladder cancer	0.000684	0.000882	CcSEcCtD
Alprazolam—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000683	0.00088	CcSEcCtD
Alprazolam—Asthenia—Cisplatin—urinary bladder cancer	0.000682	0.000878	CcSEcCtD
Alprazolam—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000681	0.000878	CcSEcCtD
Alprazolam—Sweating—Doxorubicin—urinary bladder cancer	0.000679	0.000874	CcSEcCtD
Alprazolam—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000678	0.000874	CcSEcCtD
Alprazolam—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000677	0.000872	CcSEcCtD
Alprazolam—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000675	0.00087	CcSEcCtD
Alprazolam—Urethral disorder—Epirubicin—urinary bladder cancer	0.000673	0.000867	CcSEcCtD
Alprazolam—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000669	0.000863	CcSEcCtD
Alprazolam—Epistaxis—Doxorubicin—urinary bladder cancer	0.000668	0.00086	CcSEcCtD
Alprazolam—Angiopathy—Methotrexate—urinary bladder cancer	0.000666	0.000858	CcSEcCtD
Alprazolam—Dizziness—Fluorouracil—urinary bladder cancer	0.000663	0.000854	CcSEcCtD
Alprazolam—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000661	0.000852	CcSEcCtD
Alprazolam—Chills—Methotrexate—urinary bladder cancer	0.000659	0.000848	CcSEcCtD
Alprazolam—Diarrhoea—Cisplatin—urinary bladder cancer	0.00065	0.000838	CcSEcCtD
Alprazolam—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000649	0.000837	CcSEcCtD
Alprazolam—Vomiting—Gemcitabine—urinary bladder cancer	0.000648	0.000835	CcSEcCtD
Alprazolam—Mental disorder—Methotrexate—urinary bladder cancer	0.000643	0.000828	CcSEcCtD
Alprazolam—Rash—Gemcitabine—urinary bladder cancer	0.000643	0.000828	CcSEcCtD
Alprazolam—Dermatitis—Gemcitabine—urinary bladder cancer	0.000642	0.000827	CcSEcCtD
Alprazolam—Eye disorder—Epirubicin—urinary bladder cancer	0.000642	0.000827	CcSEcCtD
Alprazolam—Hypersensitivity—Etoposide—urinary bladder cancer	0.000641	0.000826	CcSEcCtD
Alprazolam—Tinnitus—Epirubicin—urinary bladder cancer	0.00064	0.000825	CcSEcCtD
Alprazolam—Malnutrition—Methotrexate—urinary bladder cancer	0.000639	0.000823	CcSEcCtD
Alprazolam—Headache—Gemcitabine—urinary bladder cancer	0.000639	0.000823	CcSEcCtD
Alprazolam—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000637	0.000821	CcSEcCtD
Alprazolam—Vomiting—Fluorouracil—urinary bladder cancer	0.000637	0.000821	CcSEcCtD
Alprazolam—Hepatitis—Doxorubicin—urinary bladder cancer	0.000635	0.000819	CcSEcCtD
Alprazolam—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000632	0.000815	CcSEcCtD
Alprazolam—Rash—Fluorouracil—urinary bladder cancer	0.000632	0.000814	CcSEcCtD
Alprazolam—Dermatitis—Fluorouracil—urinary bladder cancer	0.000631	0.000813	CcSEcCtD
Alprazolam—Headache—Fluorouracil—urinary bladder cancer	0.000628	0.000809	CcSEcCtD
Alprazolam—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000628	0.000809	CcSEcCtD
Alprazolam—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000626	0.000807	CcSEcCtD
Alprazolam—Asthenia—Etoposide—urinary bladder cancer	0.000625	0.000805	CcSEcCtD
Alprazolam—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000624	0.000805	CcSEcCtD
Alprazolam—Angiopathy—Epirubicin—urinary bladder cancer	0.000623	0.000803	CcSEcCtD
Alprazolam—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000623	0.000803	CcSEcCtD
Alprazolam—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000619	0.000798	CcSEcCtD
Alprazolam—Back pain—Methotrexate—urinary bladder cancer	0.000618	0.000796	CcSEcCtD
Alprazolam—Chills—Epirubicin—urinary bladder cancer	0.000616	0.000794	CcSEcCtD
Alprazolam—Pruritus—Etoposide—urinary bladder cancer	0.000616	0.000793	CcSEcCtD
Alprazolam—Nausea—Gemcitabine—urinary bladder cancer	0.000606	0.00078	CcSEcCtD
Alprazolam—Vomiting—Cisplatin—urinary bladder cancer	0.000604	0.000778	CcSEcCtD
Alprazolam—Vision blurred—Methotrexate—urinary bladder cancer	0.000602	0.000776	CcSEcCtD
Alprazolam—Mental disorder—Epirubicin—urinary bladder cancer	0.000602	0.000775	CcSEcCtD
Alprazolam—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000601	0.000774	CcSEcCtD
Alprazolam—Rash—Cisplatin—urinary bladder cancer	0.000599	0.000772	CcSEcCtD
Alprazolam—Dermatitis—Cisplatin—urinary bladder cancer	0.000599	0.000771	CcSEcCtD
Alprazolam—Malnutrition—Epirubicin—urinary bladder cancer	0.000598	0.00077	CcSEcCtD
Alprazolam—Diarrhoea—Etoposide—urinary bladder cancer	0.000596	0.000767	CcSEcCtD
Alprazolam—Nausea—Fluorouracil—urinary bladder cancer	0.000595	0.000767	CcSEcCtD
Alprazolam—Eye disorder—Doxorubicin—urinary bladder cancer	0.000594	0.000765	CcSEcCtD
Alprazolam—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000593	0.000764	CcSEcCtD
Alprazolam—Tinnitus—Doxorubicin—urinary bladder cancer	0.000593	0.000763	CcSEcCtD
Alprazolam—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00059	0.00076	CcSEcCtD
Alprazolam—Tension—Epirubicin—urinary bladder cancer	0.000587	0.000756	CcSEcCtD
Alprazolam—Nervousness—Epirubicin—urinary bladder cancer	0.000581	0.000748	CcSEcCtD
Alprazolam—Back pain—Epirubicin—urinary bladder cancer	0.000578	0.000745	CcSEcCtD
Alprazolam—Angiopathy—Doxorubicin—urinary bladder cancer	0.000577	0.000743	CcSEcCtD
Alprazolam—Malaise—Methotrexate—urinary bladder cancer	0.000576	0.000742	CcSEcCtD
Alprazolam—Dizziness—Etoposide—urinary bladder cancer	0.000576	0.000742	CcSEcCtD
Alprazolam—Muscle spasms—Epirubicin—urinary bladder cancer	0.000575	0.000741	CcSEcCtD
Alprazolam—Vertigo—Methotrexate—urinary bladder cancer	0.000574	0.00074	CcSEcCtD
Alprazolam—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000573	0.000738	CcSEcCtD
Alprazolam—Chills—Doxorubicin—urinary bladder cancer	0.00057	0.000735	CcSEcCtD
Alprazolam—Nausea—Cisplatin—urinary bladder cancer	0.000564	0.000727	CcSEcCtD
Alprazolam—Vision blurred—Epirubicin—urinary bladder cancer	0.000563	0.000726	CcSEcCtD
Alprazolam—Mental disorder—Doxorubicin—urinary bladder cancer	0.000557	0.000717	CcSEcCtD
Alprazolam—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000555	0.000715	CcSEcCtD
Alprazolam—Convulsion—Methotrexate—urinary bladder cancer	0.000554	0.000713	CcSEcCtD
Alprazolam—Vomiting—Etoposide—urinary bladder cancer	0.000553	0.000713	CcSEcCtD
Alprazolam—Malnutrition—Doxorubicin—urinary bladder cancer	0.000553	0.000713	CcSEcCtD
Alprazolam—Agitation—Epirubicin—urinary bladder cancer	0.000549	0.000708	CcSEcCtD
Alprazolam—Rash—Etoposide—urinary bladder cancer	0.000549	0.000707	CcSEcCtD
Alprazolam—Dermatitis—Etoposide—urinary bladder cancer	0.000548	0.000707	CcSEcCtD
Alprazolam—Headache—Etoposide—urinary bladder cancer	0.000545	0.000703	CcSEcCtD
Alprazolam—Myalgia—Methotrexate—urinary bladder cancer	0.000544	0.000701	CcSEcCtD
Alprazolam—Chest pain—Methotrexate—urinary bladder cancer	0.000544	0.000701	CcSEcCtD
Alprazolam—Arthralgia—Methotrexate—urinary bladder cancer	0.000544	0.000701	CcSEcCtD
Alprazolam—Tension—Doxorubicin—urinary bladder cancer	0.000543	0.000699	CcSEcCtD
Alprazolam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00054	0.000696	CcSEcCtD
Alprazolam—Malaise—Epirubicin—urinary bladder cancer	0.000539	0.000695	CcSEcCtD
Alprazolam—Discomfort—Methotrexate—urinary bladder cancer	0.000537	0.000692	CcSEcCtD
Alprazolam—Nervousness—Doxorubicin—urinary bladder cancer	0.000537	0.000692	CcSEcCtD
Alprazolam—Vertigo—Epirubicin—urinary bladder cancer	0.000537	0.000692	CcSEcCtD
Alprazolam—Syncope—Epirubicin—urinary bladder cancer	0.000536	0.000691	CcSEcCtD
Alprazolam—Back pain—Doxorubicin—urinary bladder cancer	0.000535	0.000689	CcSEcCtD
Alprazolam—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000532	0.000685	CcSEcCtD
Alprazolam—Palpitations—Epirubicin—urinary bladder cancer	0.000528	0.000681	CcSEcCtD
Alprazolam—Confusional state—Methotrexate—urinary bladder cancer	0.000526	0.000677	CcSEcCtD
Alprazolam—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000525	0.000677	CcSEcCtD
Alprazolam—Vision blurred—Doxorubicin—urinary bladder cancer	0.000521	0.000672	CcSEcCtD
Alprazolam—Convulsion—Epirubicin—urinary bladder cancer	0.000518	0.000667	CcSEcCtD
Alprazolam—Infection—Methotrexate—urinary bladder cancer	0.000518	0.000667	CcSEcCtD
Alprazolam—Nausea—Etoposide—urinary bladder cancer	0.000517	0.000666	CcSEcCtD
Alprazolam—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000513	0.000661	CcSEcCtD
Alprazolam—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000511	0.000659	CcSEcCtD
Alprazolam—Myalgia—Epirubicin—urinary bladder cancer	0.000509	0.000656	CcSEcCtD
Alprazolam—Chest pain—Epirubicin—urinary bladder cancer	0.000509	0.000656	CcSEcCtD
Alprazolam—Arthralgia—Epirubicin—urinary bladder cancer	0.000509	0.000656	CcSEcCtD
Alprazolam—Agitation—Doxorubicin—urinary bladder cancer	0.000508	0.000655	CcSEcCtD
Alprazolam—Anxiety—Epirubicin—urinary bladder cancer	0.000507	0.000654	CcSEcCtD
Alprazolam—Skin disorder—Methotrexate—urinary bladder cancer	0.000506	0.000653	CcSEcCtD
Alprazolam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000505	0.000651	CcSEcCtD
Alprazolam—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000504	0.000649	CcSEcCtD
Alprazolam—Discomfort—Epirubicin—urinary bladder cancer	0.000503	0.000648	CcSEcCtD
Alprazolam—Malaise—Doxorubicin—urinary bladder cancer	0.000499	0.000643	CcSEcCtD
Alprazolam—Dry mouth—Epirubicin—urinary bladder cancer	0.000498	0.000641	CcSEcCtD
Alprazolam—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000497	0.00682	CbGpPWpGaD
Alprazolam—Vertigo—Doxorubicin—urinary bladder cancer	0.000497	0.00064	CcSEcCtD
Alprazolam—Anorexia—Methotrexate—urinary bladder cancer	0.000497	0.00064	CcSEcCtD
Alprazolam—Syncope—Doxorubicin—urinary bladder cancer	0.000496	0.000639	CcSEcCtD
Alprazolam—Confusional state—Epirubicin—urinary bladder cancer	0.000492	0.000634	CcSEcCtD
Alprazolam—CYP3A5—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000491	0.00673	CbGpPWpGaD
Alprazolam—Palpitations—Doxorubicin—urinary bladder cancer	0.000489	0.00063	CcSEcCtD
Alprazolam—Oedema—Epirubicin—urinary bladder cancer	0.000488	0.000629	CcSEcCtD
Alprazolam—Hypotension—Methotrexate—urinary bladder cancer	0.000487	0.000628	CcSEcCtD
Alprazolam—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000486	0.000626	CcSEcCtD
Alprazolam—Infection—Epirubicin—urinary bladder cancer	0.000485	0.000625	CcSEcCtD
Alprazolam—Shock—Epirubicin—urinary bladder cancer	0.00048	0.000619	CcSEcCtD
Alprazolam—Convulsion—Doxorubicin—urinary bladder cancer	0.000479	0.000618	CcSEcCtD
Alprazolam—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000479	0.000617	CcSEcCtD
Alprazolam—Tachycardia—Epirubicin—urinary bladder cancer	0.000476	0.000614	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000475	0.000612	CcSEcCtD
Alprazolam—Skin disorder—Epirubicin—urinary bladder cancer	0.000474	0.000611	CcSEcCtD
Alprazolam—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000472	0.000608	CcSEcCtD
Alprazolam—Insomnia—Methotrexate—urinary bladder cancer	0.000472	0.000608	CcSEcCtD
Alprazolam—Chest pain—Doxorubicin—urinary bladder cancer	0.000471	0.000607	CcSEcCtD
Alprazolam—Arthralgia—Doxorubicin—urinary bladder cancer	0.000471	0.000607	CcSEcCtD
Alprazolam—Myalgia—Doxorubicin—urinary bladder cancer	0.000471	0.000607	CcSEcCtD
Alprazolam—Anxiety—Doxorubicin—urinary bladder cancer	0.000469	0.000605	CcSEcCtD
Alprazolam—Paraesthesia—Methotrexate—urinary bladder cancer	0.000468	0.000603	CcSEcCtD
Alprazolam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000468	0.000603	CcSEcCtD
Alprazolam—Discomfort—Doxorubicin—urinary bladder cancer	0.000465	0.0006	CcSEcCtD
Alprazolam—Anorexia—Epirubicin—urinary bladder cancer	0.000465	0.000599	CcSEcCtD
Alprazolam—Dyspnoea—Methotrexate—urinary bladder cancer	0.000465	0.000599	CcSEcCtD
Alprazolam—Somnolence—Methotrexate—urinary bladder cancer	0.000464	0.000597	CcSEcCtD
Alprazolam—GABRA1—Ion channel transport—TRPV1—urinary bladder cancer	0.000463	0.00635	CbGpPWpGaD
Alprazolam—Dry mouth—Doxorubicin—urinary bladder cancer	0.000461	0.000593	CcSEcCtD
Alprazolam—Dyspepsia—Methotrexate—urinary bladder cancer	0.000459	0.000591	CcSEcCtD
Alprazolam—Hypotension—Epirubicin—urinary bladder cancer	0.000456	0.000587	CcSEcCtD
Alprazolam—CYP3A5—Biological oxidations—UGT2B7—urinary bladder cancer	0.000455	0.00624	CbGpPWpGaD
Alprazolam—Confusional state—Doxorubicin—urinary bladder cancer	0.000455	0.000587	CcSEcCtD
Alprazolam—Decreased appetite—Methotrexate—urinary bladder cancer	0.000453	0.000584	CcSEcCtD
Alprazolam—Oedema—Doxorubicin—urinary bladder cancer	0.000451	0.000582	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00045	0.00058	CcSEcCtD
Alprazolam—Fatigue—Methotrexate—urinary bladder cancer	0.00045	0.000579	CcSEcCtD
Alprazolam—CYP3A5—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000449	0.00616	CbGpPWpGaD
Alprazolam—Infection—Doxorubicin—urinary bladder cancer	0.000449	0.000578	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000445	0.000573	CcSEcCtD
Alprazolam—Shock—Doxorubicin—urinary bladder cancer	0.000444	0.000572	CcSEcCtD
Alprazolam—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000443	0.00057	CcSEcCtD
Alprazolam—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000443	0.00607	CbGpPWpGaD
Alprazolam—Insomnia—Epirubicin—urinary bladder cancer	0.000441	0.000569	CcSEcCtD
Alprazolam—Tachycardia—Doxorubicin—urinary bladder cancer	0.000441	0.000568	CcSEcCtD
Alprazolam—Skin disorder—Doxorubicin—urinary bladder cancer	0.000439	0.000565	CcSEcCtD
Alprazolam—Paraesthesia—Epirubicin—urinary bladder cancer	0.000438	0.000565	CcSEcCtD
Alprazolam—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000437	0.00599	CbGpPWpGaD
Alprazolam—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000436	0.000562	CcSEcCtD
Alprazolam—Dyspnoea—Epirubicin—urinary bladder cancer	0.000435	0.000561	CcSEcCtD
Alprazolam—Somnolence—Epirubicin—urinary bladder cancer	0.000434	0.000559	CcSEcCtD
Alprazolam—Anorexia—Doxorubicin—urinary bladder cancer	0.00043	0.000554	CcSEcCtD
Alprazolam—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00043	0.000554	CcSEcCtD
Alprazolam—Dyspepsia—Epirubicin—urinary bladder cancer	0.00043	0.000553	CcSEcCtD
Alprazolam—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000426	0.000549	CcSEcCtD
Alprazolam—Decreased appetite—Epirubicin—urinary bladder cancer	0.000424	0.000547	CcSEcCtD
Alprazolam—Hypotension—Doxorubicin—urinary bladder cancer	0.000422	0.000544	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000421	0.000543	CcSEcCtD
Alprazolam—Fatigue—Epirubicin—urinary bladder cancer	0.000421	0.000542	CcSEcCtD
Alprazolam—Constipation—Epirubicin—urinary bladder cancer	0.000417	0.000538	CcSEcCtD
Alprazolam—Urticaria—Methotrexate—urinary bladder cancer	0.000414	0.000534	CcSEcCtD
Alprazolam—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000413	0.00566	CbGpPWpGaD
Alprazolam—Abdominal pain—Methotrexate—urinary bladder cancer	0.000412	0.000531	CcSEcCtD
Alprazolam—Body temperature increased—Methotrexate—urinary bladder cancer	0.000412	0.000531	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000411	0.00053	CcSEcCtD
Alprazolam—CYP3A5—Biological oxidations—CYP4B1—urinary bladder cancer	0.00041	0.00562	CbGpPWpGaD
Alprazolam—Insomnia—Doxorubicin—urinary bladder cancer	0.000408	0.000526	CcSEcCtD
Alprazolam—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000405	0.000522	CcSEcCtD
Alprazolam—CYP3A5—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000404	0.00554	CbGpPWpGaD
Alprazolam—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000403	0.000519	CcSEcCtD
Alprazolam—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000402	0.000518	CcSEcCtD
Alprazolam—Somnolence—Doxorubicin—urinary bladder cancer	0.000401	0.000517	CcSEcCtD
Alprazolam—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000399	0.000514	CcSEcCtD
Alprazolam—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000397	0.000512	CcSEcCtD
Alprazolam—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000392	0.000506	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00039	0.000502	CcSEcCtD
Alprazolam—Fatigue—Doxorubicin—urinary bladder cancer	0.000389	0.000502	CcSEcCtD
Alprazolam—Urticaria—Epirubicin—urinary bladder cancer	0.000388	0.000499	CcSEcCtD
Alprazolam—Constipation—Doxorubicin—urinary bladder cancer	0.000386	0.000497	CcSEcCtD
Alprazolam—Body temperature increased—Epirubicin—urinary bladder cancer	0.000386	0.000497	CcSEcCtD
Alprazolam—Abdominal pain—Epirubicin—urinary bladder cancer	0.000386	0.000497	CcSEcCtD
Alprazolam—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000384	0.000495	CcSEcCtD
Alprazolam—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000381	0.00522	CbGpPWpGaD
Alprazolam—CYP3A7—Biological oxidations—NAT2—urinary bladder cancer	0.000377	0.00517	CbGpPWpGaD
Alprazolam—Asthenia—Methotrexate—urinary bladder cancer	0.000374	0.000482	CcSEcCtD
Alprazolam—CYP3A7—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000372	0.0051	CbGpPWpGaD
Alprazolam—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000372	0.000479	CcSEcCtD
Alprazolam—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.00037	0.00507	CbGpPWpGaD
Alprazolam—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000369	0.000476	CcSEcCtD
Alprazolam—Pruritus—Methotrexate—urinary bladder cancer	0.000369	0.000475	CcSEcCtD
Alprazolam—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000365	0.005	CbGpPWpGaD
Alprazolam—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000359	0.000463	CcSEcCtD
Alprazolam—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000359	0.00492	CbGpPWpGaD
Alprazolam—Urticaria—Doxorubicin—urinary bladder cancer	0.000359	0.000462	CcSEcCtD
Alprazolam—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000357	0.0049	CbGpPWpGaD
Alprazolam—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000357	0.00046	CcSEcCtD
Alprazolam—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000357	0.00046	CcSEcCtD
Alprazolam—Diarrhoea—Methotrexate—urinary bladder cancer	0.000357	0.00046	CcSEcCtD
Alprazolam—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000351	0.00481	CbGpPWpGaD
Alprazolam—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000351	0.00481	CbGpPWpGaD
Alprazolam—Asthenia—Epirubicin—urinary bladder cancer	0.00035	0.000451	CcSEcCtD
Alprazolam—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000346	0.00474	CbGpPWpGaD
Alprazolam—Pruritus—Epirubicin—urinary bladder cancer	0.000345	0.000445	CcSEcCtD
Alprazolam—Dizziness—Methotrexate—urinary bladder cancer	0.000345	0.000444	CcSEcCtD
Alprazolam—GABRB2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000342	0.00469	CbGpPWpGaD
Alprazolam—Diarrhoea—Epirubicin—urinary bladder cancer	0.000334	0.00043	CcSEcCtD
Alprazolam—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000333	0.000429	CcSEcCtD
Alprazolam—GABRA5—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000332	0.00456	CbGpPWpGaD
Alprazolam—Vomiting—Methotrexate—urinary bladder cancer	0.000332	0.000427	CcSEcCtD
Alprazolam—Rash—Methotrexate—urinary bladder cancer	0.000329	0.000424	CcSEcCtD
Alprazolam—Dermatitis—Methotrexate—urinary bladder cancer	0.000328	0.000423	CcSEcCtD
Alprazolam—Headache—Methotrexate—urinary bladder cancer	0.000327	0.000421	CcSEcCtD
Alprazolam—GABRA3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000326	0.00447	CbGpPWpGaD
Alprazolam—Asthenia—Doxorubicin—urinary bladder cancer	0.000324	0.000417	CcSEcCtD
Alprazolam—Dizziness—Epirubicin—urinary bladder cancer	0.000323	0.000416	CcSEcCtD
Alprazolam—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000321	0.0044	CbGpPWpGaD
Alprazolam—GABRA2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000321	0.0044	CbGpPWpGaD
Alprazolam—Pruritus—Doxorubicin—urinary bladder cancer	0.000319	0.000412	CcSEcCtD
Alprazolam—GABRB3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000319	0.00437	CbGpPWpGaD
Alprazolam—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000317	0.00434	CbGpPWpGaD
Alprazolam—GABRG2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000313	0.00429	CbGpPWpGaD
Alprazolam—Vomiting—Epirubicin—urinary bladder cancer	0.00031	0.0004	CcSEcCtD
Alprazolam—Nausea—Methotrexate—urinary bladder cancer	0.00031	0.000399	CcSEcCtD
Alprazolam—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000309	0.000398	CcSEcCtD
Alprazolam—Rash—Epirubicin—urinary bladder cancer	0.000308	0.000396	CcSEcCtD
Alprazolam—Dermatitis—Epirubicin—urinary bladder cancer	0.000307	0.000396	CcSEcCtD
Alprazolam—Headache—Epirubicin—urinary bladder cancer	0.000306	0.000394	CcSEcCtD
Alprazolam—CYP3A7—Biological oxidations—HPGDS—urinary bladder cancer	0.000302	0.00414	CbGpPWpGaD
Alprazolam—Dizziness—Doxorubicin—urinary bladder cancer	0.000299	0.000385	CcSEcCtD
Alprazolam—CYP3A7—Biological oxidations—GSTT1—urinary bladder cancer	0.000293	0.00401	CbGpPWpGaD
Alprazolam—Nausea—Epirubicin—urinary bladder cancer	0.00029	0.000373	CcSEcCtD
Alprazolam—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000289	0.00396	CbGpPWpGaD
Alprazolam—Vomiting—Doxorubicin—urinary bladder cancer	0.000287	0.00037	CcSEcCtD
Alprazolam—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000285	0.00391	CbGpPWpGaD
Alprazolam—Rash—Doxorubicin—urinary bladder cancer	0.000285	0.000367	CcSEcCtD
Alprazolam—Dermatitis—Doxorubicin—urinary bladder cancer	0.000284	0.000366	CcSEcCtD
Alprazolam—GABRA1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000284	0.00389	CbGpPWpGaD
Alprazolam—Headache—Doxorubicin—urinary bladder cancer	0.000283	0.000364	CcSEcCtD
Alprazolam—GABRA1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000273	0.00375	CbGpPWpGaD
Alprazolam—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	0.000273	0.00374	CbGpPWpGaD
Alprazolam—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000269	0.00369	CbGpPWpGaD
Alprazolam—Nausea—Doxorubicin—urinary bladder cancer	0.000268	0.000346	CcSEcCtD
Alprazolam—GABRB2—Orphan transporters—CREBBP—urinary bladder cancer	0.000261	0.00358	CbGpPWpGaD
Alprazolam—GABRA5—Orphan transporters—CREBBP—urinary bladder cancer	0.000254	0.00348	CbGpPWpGaD
Alprazolam—GABRA3—Orphan transporters—CREBBP—urinary bladder cancer	0.000249	0.00341	CbGpPWpGaD
Alprazolam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000249	0.00341	CbGpPWpGaD
Alprazolam—GABRB2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000247	0.00339	CbGpPWpGaD
Alprazolam—GABRA2—Orphan transporters—CREBBP—urinary bladder cancer	0.000245	0.00335	CbGpPWpGaD
Alprazolam—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000244	0.00335	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000244	0.00335	CbGpPWpGaD
Alprazolam—GABRB3—Orphan transporters—CREBBP—urinary bladder cancer	0.000243	0.00333	CbGpPWpGaD
Alprazolam—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000241	0.0033	CbGpPWpGaD
Alprazolam—GABRA5—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00024	0.00329	CbGpPWpGaD
Alprazolam—GABRG2—Orphan transporters—CREBBP—urinary bladder cancer	0.000239	0.00327	CbGpPWpGaD
Alprazolam—GABRA3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000236	0.00323	CbGpPWpGaD
Alprazolam—GABRA2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000232	0.00318	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000231	0.00317	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000231	0.00317	CbGpPWpGaD
Alprazolam—GABRB3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00023	0.00316	CbGpPWpGaD
Alprazolam—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000228	0.00313	CbGpPWpGaD
Alprazolam—GABRG2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000226	0.0031	CbGpPWpGaD
Alprazolam—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	0.000218	0.00299	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000212	0.0029	CbGpPWpGaD
Alprazolam—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	0.000212	0.0029	CbGpPWpGaD
Alprazolam—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000209	0.00286	CbGpPWpGaD
Alprazolam—GABRA1—Orphan transporters—CREBBP—urinary bladder cancer	0.000209	0.00286	CbGpPWpGaD
Alprazolam—CYP3A7—Biological oxidations—GSTP1—urinary bladder cancer	0.000203	0.00278	CbGpPWpGaD
Alprazolam—GABRB2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000202	0.00276	CbGpPWpGaD
Alprazolam—CYP3A7—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.0002	0.00274	CbGpPWpGaD
Alprazolam—GABRA1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000198	0.00271	CbGpPWpGaD
Alprazolam—GABRA5—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000196	0.00268	CbGpPWpGaD
Alprazolam—GABRA3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000192	0.00264	CbGpPWpGaD
Alprazolam—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000192	0.00264	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000191	0.00261	CbGpPWpGaD
Alprazolam—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00019	0.0026	CbGpPWpGaD
Alprazolam—GABRA2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000189	0.00259	CbGpPWpGaD
Alprazolam—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000188	0.00258	CbGpPWpGaD
Alprazolam—GABRB3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000188	0.00257	CbGpPWpGaD
Alprazolam—CYP3A7—Biological oxidations—GSTM1—urinary bladder cancer	0.000186	0.00255	CbGpPWpGaD
Alprazolam—GABRG2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000184	0.00253	CbGpPWpGaD
Alprazolam—CYP3A7—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000184	0.00252	CbGpPWpGaD
Alprazolam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000164	0.00225	CbGpPWpGaD
Alprazolam—GABRA1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000161	0.00221	CbGpPWpGaD
Alprazolam—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000154	0.00211	CbGpPWpGaD
Alprazolam—GABRA1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000151	0.00207	CbGpPWpGaD
Alprazolam—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000149	0.00204	CbGpPWpGaD
Alprazolam—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000147	0.00201	CbGpPWpGaD
Alprazolam—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000145	0.00198	CbGpPWpGaD
Alprazolam—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000144	0.00197	CbGpPWpGaD
Alprazolam—GABRB2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000136	0.00187	CbGpPWpGaD
Alprazolam—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000135	0.00185	CbGpPWpGaD
Alprazolam—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000133	0.00182	CbGpPWpGaD
Alprazolam—GABRA5—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000132	0.00181	CbGpPWpGaD
Alprazolam—GABRA3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00013	0.00178	CbGpPWpGaD
Alprazolam—GABRA2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000128	0.00175	CbGpPWpGaD
Alprazolam—GABRB3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000127	0.00174	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000127	0.00174	CbGpPWpGaD
Alprazolam—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000125	0.00171	CbGpPWpGaD
Alprazolam—GABRG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000125	0.00171	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—GSTZ1—urinary bladder cancer	0.000124	0.0017	CbGpPWpGaD
Alprazolam—GABRB3—BDNF signaling pathway—SRC—urinary bladder cancer	0.000124	0.0017	CbGpPWpGaD
Alprazolam—GABRA1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.00012	0.00164	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—GSTO2—urinary bladder cancer	0.000118	0.00161	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—NAT1—urinary bladder cancer	0.000118	0.00161	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000111	0.00152	CbGpPWpGaD
Alprazolam—GABRA1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000109	0.00149	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	0.000108	0.00148	CbGpPWpGaD
Alprazolam—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000103	0.00142	CbGpPWpGaD
Alprazolam—GABRA1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000103	0.00141	CbGpPWpGaD
Alprazolam—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000102	0.0014	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000101	0.00139	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	9.83e-05	0.00135	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	9.7e-05	0.00133	CbGpPWpGaD
Alprazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	9.59e-05	0.00131	CbGpPWpGaD
Alprazolam—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	9.5e-05	0.0013	CbGpPWpGaD
Alprazolam—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.37e-05	0.00128	CbGpPWpGaD
Alprazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	9.32e-05	0.00128	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	9.16e-05	0.00126	CbGpPWpGaD
Alprazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	9.15e-05	0.00125	CbGpPWpGaD
Alprazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	8.99e-05	0.00123	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	8.98e-05	0.00123	CbGpPWpGaD
Alprazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	8.93e-05	0.00122	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	8.93e-05	0.00122	CbGpPWpGaD
Alprazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	8.77e-05	0.0012	CbGpPWpGaD
Alprazolam—GABRB3—BDNF signaling pathway—HRAS—urinary bladder cancer	8.74e-05	0.0012	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	8.51e-05	0.00117	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—NAT1—urinary bladder cancer	8.51e-05	0.00117	CbGpPWpGaD
Alprazolam—GABRA1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	8.34e-05	0.00114	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	7.79e-05	0.00107	CbGpPWpGaD
Alprazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	7.67e-05	0.00105	CbGpPWpGaD
Alprazolam—GABRB2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.21e-05	0.000988	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—TYMP—urinary bladder cancer	7.14e-05	0.000978	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	7.01e-05	0.000961	CbGpPWpGaD
Alprazolam—GABRA5—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.01e-05	0.00096	CbGpPWpGaD
Alprazolam—GABRA3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.88e-05	0.000943	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	6.82e-05	0.000934	CbGpPWpGaD
Alprazolam—GABRA2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.76e-05	0.000927	CbGpPWpGaD
Alprazolam—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.72e-05	0.000921	CbGpPWpGaD
Alprazolam—GABRB3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.72e-05	0.000921	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	6.62e-05	0.000908	CbGpPWpGaD
Alprazolam—GABRG2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.6e-05	0.000904	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—NAT2—urinary bladder cancer	6.45e-05	0.000885	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	6.45e-05	0.000884	CbGpPWpGaD
Alprazolam—GABRB2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.37e-05	0.000874	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	6.33e-05	0.000868	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	6.26e-05	0.000859	CbGpPWpGaD
Alprazolam—GABRA5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.19e-05	0.000849	CbGpPWpGaD
Alprazolam—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.18e-05	0.000847	CbGpPWpGaD
Alprazolam—GABRA3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.08e-05	0.000833	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	6e-05	0.000823	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—NAT1—urinary bladder cancer	6e-05	0.000823	CbGpPWpGaD
Alprazolam—GABRA2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.97e-05	0.000819	CbGpPWpGaD
Alprazolam—GABRB3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.94e-05	0.000814	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.9e-05	0.000809	CbGpPWpGaD
Alprazolam—GABRG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.83e-05	0.000799	CbGpPWpGaD
Alprazolam—GABRA1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.76e-05	0.00079	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—RRM2—urinary bladder cancer	5.57e-05	0.000764	CbGpPWpGaD
Alprazolam—GABRB2—Neuronal System—HRAS—urinary bladder cancer	5.53e-05	0.000757	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	5.49e-05	0.000752	CbGpPWpGaD
Alprazolam—GABRA5—Neuronal System—HRAS—urinary bladder cancer	5.37e-05	0.000736	CbGpPWpGaD
Alprazolam—GABRA3—Neuronal System—HRAS—urinary bladder cancer	5.27e-05	0.000723	CbGpPWpGaD
Alprazolam—GABRA2—Neuronal System—HRAS—urinary bladder cancer	5.18e-05	0.00071	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—ENO2—urinary bladder cancer	5.16e-05	0.000707	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	5.16e-05	0.000707	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—TYMP—urinary bladder cancer	5.16e-05	0.000707	CbGpPWpGaD
Alprazolam—GABRB3—Neuronal System—HRAS—urinary bladder cancer	5.15e-05	0.000705	CbGpPWpGaD
Alprazolam—GABRA1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.09e-05	0.000698	CbGpPWpGaD
Alprazolam—GABRG2—Neuronal System—HRAS—urinary bladder cancer	5.05e-05	0.000693	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	5e-05	0.000686	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	4.94e-05	0.000677	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.67e-05	0.00064	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—NAT2—urinary bladder cancer	4.66e-05	0.000639	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.55e-05	0.000623	CbGpPWpGaD
Alprazolam—GABRA1—Neuronal System—HRAS—urinary bladder cancer	4.42e-05	0.000605	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.18e-05	0.000572	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—NQO1—urinary bladder cancer	4.16e-05	0.00057	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—RRM2—urinary bladder cancer	4.03e-05	0.000552	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.96e-05	0.000543	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.96e-05	0.000543	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—ENO2—urinary bladder cancer	3.73e-05	0.000511	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	3.73e-05	0.000511	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.65e-05	0.0005	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.64e-05	0.000498	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.62e-05	0.000496	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	3.62e-05	0.000496	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.49e-05	0.000479	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	3.47e-05	0.000475	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.29e-05	0.000451	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.26e-05	0.000447	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—TYMS—urinary bladder cancer	3.22e-05	0.000442	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	3.19e-05	0.000437	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	3.19e-05	0.000437	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.08e-05	0.000422	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—GPX1—urinary bladder cancer	3.05e-05	0.000418	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.01e-05	0.000412	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3e-05	0.000411	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	3e-05	0.000411	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.84e-05	0.000389	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	2.82e-05	0.000386	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.63e-05	0.00036	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.63e-05	0.00036	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.61e-05	0.000358	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.55e-05	0.00035	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.51e-05	0.000344	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	2.51e-05	0.000344	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.4e-05	0.000329	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—TYMS—urinary bladder cancer	2.33e-05	0.000319	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.3e-05	0.000316	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.3e-05	0.000316	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—PPARG—urinary bladder cancer	2.28e-05	0.000313	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.21e-05	0.000302	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	2.19e-05	0.000301	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.17e-05	0.000297	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.17e-05	0.000297	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.12e-05	0.00029	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.06e-05	0.000282	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.04e-05	0.000279	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.87e-05	0.000257	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.8e-05	0.000246	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.79e-05	0.000246	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.77e-05	0.000242	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.73e-05	0.000238	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.73e-05	0.000238	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.71e-05	0.000234	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.68e-05	0.000231	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.65e-05	0.000226	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.64e-05	0.000225	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.62e-05	0.000223	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.62e-05	0.000223	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.59e-05	0.000217	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.57e-05	0.000215	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.56e-05	0.000213	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.53e-05	0.000209	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.49e-05	0.000205	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.44e-05	0.000197	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.4e-05	0.000192	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.3e-05	0.000178	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.17e-05	0.00016	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.16e-05	0.00016	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.13e-05	0.000155	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.12e-05	0.000153	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.08e-05	0.000149	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.08e-05	0.000148	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.07e-05	0.000147	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.07e-05	0.000147	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.03e-05	0.000141	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.01e-05	0.000138	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	9.47e-06	0.00013	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	9.16e-06	0.000126	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—PTEN—urinary bladder cancer	7.99e-06	0.000109	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.68e-06	0.000105	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—EP300—urinary bladder cancer	7.62e-06	0.000104	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	7.37e-06	0.000101	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.04e-06	8.28e-05	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.27e-06	7.22e-05	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.02e-06	6.88e-05	CbGpPWpGaD
